Exclusive breastfeeding among women with polycystic ovary syndrome versus women from a population-based cohort: a cohort study
Abstract
BACKGROUND: Women with polycystic ovary syndrome (PCOS) face breastfeeding challenges. We aimed to compare exclusive breastfeeding rates in women with PCOS to those in a population-based cohort, and to explore the effect of metformin and metabolic factors on exclusive breastfeeding in women with PCOS. METHODS: This cohort study included 653 women from the pilot, PregMet, and PregMet2 randomized trials on metformin in pregnant women with PCOS (2000–2017), and 63,927 women from the Norwegian Mother, Father and Child Cohort Study (MoBa) (1999–2008) as the reference group. Logistic regression estimated odds ratios for exclusive breastfeeding one month postpartum in women with PCOS versus MoBa women, and in women with PCOS randomized to metformin or placebo. RESULTS: Women with PCOS reported less exclusive breastfeeding than MoBa women one month postpartum (adjusted OR (aOR) 0.52 (0.42–0.63)). Among women of normal weight, those with PCOS breastfed to the same extent as MoBa women (aOR 0.98 (0.63–1.54)), but less in the overweight or obesity categories (aOR 0.56 (0.39–0.82) and aOR 0.55 (0.40–0.76), respectively). However, differences across weight categories were not statistically significant (p-value for interaction = 0.088). We found no difference in exclusive breastfeeding between metformin and placebo-treated women with PCOS. Hypertensive disorders and gestational diabetes did not affect exclusive breastfeeding rate in PCOS. CONCLUSIONS: Exclusive breastfeeding did not…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 63,927 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.